Infectious Complications in Head and Neck Cancer Patients Treated with Cetuximab: Propensity Score and Instrumental Variable AnalysisReport as inadecuate




Infectious Complications in Head and Neck Cancer Patients Treated with Cetuximab: Propensity Score and Instrumental Variable Analysis - Download this document for free, or read online. Document in PDF available to download.

Background

To compare the infection rates between cetuximab-treated patients with head and neck cancers HNC and untreated patients.

Methodology

A national cohort of 1083 HNC patients identified in 2010 from the Taiwan National Health Insurance Research Database was established. After patients were followed for one year, propensity score analysis and instrumental variable analysis were performed to assess the association between cetuximab therapy and the infection rates.

Results

HNC patients receiving cetuximab n = 158 were older, had lower SES, and resided more frequently in rural areas as compared to those without cetuximab therapy. 125 patients, 32 20.3% in the group using cetuximab and 93 10.1% in the group not using it presented infections. The propensity score analysis revealed a 2.3-fold adjusted odds ratio OR = 2.27; 95% CI, 1.46–3.54; P = 0.001 increased risk for infection in HNC patients treated with cetuximab. However, using IVA, the average treatment effect of cetuximab was not statistically associated with increased risk of infection OR, 0.87; 95% CI, 0.61–1.14.

Conclusions

Cetuximab therapy was not statistically associated with infection rate in HNC patients. However, older HNC patients using cetuximab may incur up to 33% infection rate during one year. Particular attention should be given to older HNC patients treated with cetuximab.



Author: Ching-Chih Lee, Hsu-Chueh Ho, Shih-Hsuan Hsiao, Tza-Ta Huang, Hon-Yi Lin, Szu-Chin Li, Pesus Chou, Yu-Chieh Su

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents